Special Issue "New Drug Discovery Era by Characterizing Substrates and Inhibitors of Multidrug Efflux Systems to Prevent Antibiotic Resistance"

A special issue of Antibiotics (ISSN 2079-6382). This special issue belongs to the section "Mechanism and Evolution of Antibiotic Resistance".

Deadline for manuscript submissions: 31 October 2021.

Special Issue Editor

Dr. Sandrine Alibert
E-Mail Website
Guest Editor
Pharmaceutical Chemistry Department, Faculty of Pharmacy, Aix Marseille University, MCT U1261 Inserm, Marseille, France
Interests: medicinal chemistry; drug discovery; drug design; antimicrobial resistance; natural products; efflux pump inhibitors; QSAR

Special Issue Information

Dear Colleagues,

Understanding antibiotic resistance in the environment is relevant to human health because of the need to predict the emergence of resistant pathogens. The presence of potentially hostile conditions in nature would induce the selection of specific or non-specific antimicrobial resistance mechanisms. Because of the selective pressure imposed by various offensive substances in their surroundings, including antibiotics, their dissemination in the air, soils, and aquatic environments also resulting from human activities can affect the prevalence of resistance mechanisms and thus the treatment of human diseases. These can be transmitted between humans, animals, and the environment. It is now known that antibiotic resistance mechanisms are associated with the main role that these molecules play in the environment, such as providing tolerance to toxic compounds. Some efflux pump families exhibit general resistance mechanisms as they expel various toxic molecules from the cells. Bacterial efflux is a major component of resistance to many classes of drug agents. Multi-drug efflux systems (MES) are membrane-transport proteins that play various physiological roles in Gram-positive and -negative bacteria. The identification and the characterization of efflux substrates and inhibitors, aided by genomics, proteomics, and metabolomics, are the subject of active and growing research. Advances made in the accumulation of data regarding MES will be the origin of a new discovery era of new therapeutic agents to fight antibiotic resistance. Publication of many studies using standardized methods is therefore essential to move towards this goal.

Dr. Sandrine Alibert
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Multi-drug efflux systems
  • Substrates
  • Inhibitors
  • Antibiotic resistance
  • Gram positive and negative bacteria
  • Drug discovery
  • Genomics
  • Proteomics
  • Metabolomics

Published Papers

This special issue is now open for submission.
Back to TopTop